跳到正文
原文
Endpoints News 生物医药· Anna Brown·· 7 天前AI 评分51

阿斯利康撤回某单抗欧洲上市申请,CHMP支持Gazyvaro用于狼疮治疗

AstraZeneca pulls EU filing for antibody as CHMP backs Gazyvaro in lupus

AI 导读

阿斯利康已撤回其针对部分淀粉样变性患者的单克隆抗体的欧洲上市申请,该候选药物此前未能通过两项后期研究。欧洲人用药委员会(CHMP)同时表示支持Gazyvaro用于治疗狼疮。

正文

As­traZeneca has with­drawn its Eu­ro­pean mar­ket­ing ap­pli­ca­tion for a mon­o­clon­al an­ti­body in a sub­set of amy­loi­do­sis pa­tients. The can­di­date had pre­vi­ous­ly failed two late-stage stud­ies …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news